Rajesh Ramanathan - Concepedia

Author

Rajesh Ramanathan

Virginia Commonwealth University ORCID

Also Known As

R K Ramanathan, R Ramanathan, R. K. Ramanathan, R. Ramanathan, R.K. Ramanathan, Rajesh Ramanathan

107

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University Virginia Commonwealth University Medical Center University of Pittsburgh Medical Center UPMC Hillman Cancer Center Roswell Park Comprehensive Cancer Center

About

Rajesh Ramanathan is an author at Virginia Commonwealth University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	37	1.7K
2	Health Sciences	7	7	351
3	Nursing	2	2	56
4	Public Health	2	2	48
5	Biomolecular Engineering	1	1	15

Rajesh Ramanathan

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Helmut Oettle, Donald Richards, Rajesh Ramanathan, Annals of Oncology UrologyOncologySurgical OncologyPancreatic CancerGastrointestinal Oncology	2005	304
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282 Rajesh Ramanathan, Avital Cnaan, R. G. Hahn, Annals of Oncology OncologyPhase Ii TrialPancreatic CancerGastrointestinal OncologyMedicine	2001	180
Generation of fully functional hepatocyte-like organoids from human induced pluripotent stem cells mixed with Endothelial Cells Giuseppe Pettinato, Sylvain Lehoux, Rajesh Ramanathan, Scientific Reports	2019	159
A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 P. J. Loehrer, Mark Powell, Higinia R. Cárdenes, Journal of Clinical Oncology Arm BRadiation MedicinePancreatic CancerRadiation TherapyGastrointestinal Oncology	2008	154
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris, European Journal of Cancer Pro-drug Sf1126MedicinePharmacologyAdvanced Solid TumoursPharmacotherapy	2012	131
Scalable Differentiation of Human iPSCs in a Multicellular Spheroid-based 3D Culture into Hepatocyte-like Cells through Direct Wnt/β-catenin Pathway Inhibition Giuseppe Pettinato, Rajesh Ramanathan, Robert A. Fisher, Scientific Reports	2016	83
Robotic Pancreaticoduodenectomy Is Associated with Decreased Clinically Relevant Pancreatic Fistulas: a Propensity-Matched Analysis Jianpeng Cai, Rajesh Ramanathan, Mazen S. Zenati, Journal of Gastrointestinal Surgery UrologyPancreatic CancerPancreatic Fluid CollectionRobotic TechnologyPropensity-matched Analysis	2019	80
A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer Donald Richards, Hedy L. Kindler, Helmut Oettle, Journal of Clinical Oncology Versus GemcitabineUrologyPancreatic CancerGastrointestinal OncologyMedicine	2004	69
Breast cancer sphingosine-1-phosphate is associated with phospho-sphingosine kinase 1 and lymphatic metastasis Junko Tsuchida, Masayuki Nagahashi, Masato Nakajima, Journal of Surgical Research Tumor BiologyBreast OncologyOncologyMedicineReceptor Tyrosine Kinase	2016	59
Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing Hiteshkumar D Patel, Merrill J. Egorin, S. C. Remick, Journal of Clinical Oncology Hepatic DysfunctionModerate HdPharmacotherapyLogistic AnalysisHematological Malignancy	2004	57

Page 1